Evidence map›Paper›PMID 23903841›Full record

ArticleJournal of virology2013

A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV.

Tiffany M Turner, Les P Jones, S Mark Tompkins, Ralph A Tripp

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Tiffany M TurnerDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Les P Jones
S Mark Tompkins
Ralph A Tripp
University of Georgia · US

Funding

NCRR NIH HHS R01-1021RR211294NIAID NIH HHS HHSN266200700006C
6 · The paper itself

Abstract

Influenza A virus and respiratory syncytial virus (RSV) cause substantial morbidity and mortality afflicting the ends of the age spectrum during the autumn through winter months in the United States. The benefit of vaccination against RSV and influenza using a subunit vaccine to enhance immunity and neutralizing antibody was investigated. Influenza virus hemagglutinin (HA) and RSV fusion (F) protein were tested as vaccine components alone and in combination to explore the adjuvant properties of RSV F protein on HA immunity. Mice vaccinated with HA and F exhibited robust immunity that, when challenged, had reduced viral burden for both influenza and RSV. These studies show an enhancing and cross-protective benefit of F protein for anti-HA immunity.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralBlotting, WesternCells, CulturedChlorocebus aethiopsHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza A virusLungMiceMice, Inbred C57BLOrthomyxoviridae InfectionsProtein SubunitsRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza Virushemagglutinin, human influenza A virusProtein SubunitsRespiratory Syncytial Virus VaccinesTlr4 protein, mouseToll-Like Receptor 4Viral Fusion Proteins

Identifiers

PMID23903841
PMCPMC3807402
OpenAlexW2022961516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.